
    
      The study consisted of 3 phases: Pre-Treatment, Treatment, and Extension. Pre-Treatment Phase
      had 2 periods: Screening and Baseline. Treatment Phase consisted of intensive PK assessment
      with eribulin mesylate given IV alone on Day 1 followed by eribulin mesylate given IV on Day
      15 with rifampicin given orally from Days 9 to 20. Extension Phase allowed eribulin mesylate
      treatment to continue for participants without progressive disease or unacceptable toxicity.
    
  